Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer

IMPORTANCE: The BEACON trial showed that combination therapy with encorafenib (BRAF inhibitor) and cetuximab (EGFR inhibitor) was associated with prolonged overall survival compared with standard chemotherapy in patients with metastatic BRAF variant colorectal cancer. However, the cost-effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Kishan K., Stein, Stacey, Lacy, Jill, O’Hara, Mark, Huntington, Scott F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804917/
https://www.ncbi.nlm.nih.gov/pubmed/33433598
http://dx.doi.org/10.1001/jamanetworkopen.2020.33441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804917/
https://www.ncbi.nlm.nih.gov/pubmed/33433598
http://dx.doi.org/10.1001/jamanetworkopen.2020.33441

Ejemplares similares